Caribou Biosciences, Inc. Proceeds from Common Stock Issued
Caribou Biosciences, Inc. (CRBU) reported Proceeds from Common Stock Issued of $20.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-13
- Caribou Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $17.92M.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $2.22M.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $4.07M, a 5.36% increase year-over-year.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for fiscal 2025 was $4.07M, a 73.21% decline from fiscal 2024.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for fiscal 2024 was $15.19M, a 1408.64% increase from fiscal 2023.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for fiscal 2023 was $1.01M.
- Caribou Biosciences, Inc. proceeds from issuance of common stock for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $20.14M 10-Q · filed 2026-08-13 | $24.21M derived: sum of 3 quarters · filed 2026-08-13 | $24.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.22M 10-Q · filed 2026-05-07 | $6.29M derived: sum of 2 quarters · filed 2026-05-07 | $6.29M derived: sum of 3 quarters · filed 2026-05-07 | $6.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.07M derived: sum of 2 quarters · filed 2026-03-05 | $4.07M derived: sum of 3 quarters · filed 2026-08-13 | $4.07M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-12 | $3.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $3.86M derived: sum of 3 quarters · filed 2026-08-13 | $3.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $3.86M derived: sum of 2 quarters · filed 2026-05-07 | $3.86M derived: sum of 3 quarters · filed 2026-05-07 | $3.86M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.86M derived: sum of 2 quarters · filed 2026-03-05 | $3.86M derived: sum of 3 quarters · filed 2026-03-05 | $15.19M 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $11.33M 10-Q · filed 2025-11-12 | $11.33M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $11.33M 10-Q · filed 2025-08-12 | $11.33M derived: sum of 3 quarters · filed 2025-08-12 | $11.33M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $11.33M 10-Q · filed 2025-05-08 | $11.33M derived: sum of 2 quarters · filed 2025-05-08 | $11.33M derived: sum of 3 quarters · filed 2025-05-08 | $11.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$1.00K derived: sum of 2 quarters · filed 2025-03-10 | -$116.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.01M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$116.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.01M 10-Q · filed 2024-11-06 | $1.01M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.01M 10-Q · filed 2024-08-06 | $1.01M derived: sum of 3 quarters · filed 2024-08-06 | $1.01M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.12M 10-Q · filed 2024-05-07 | $1.12M derived: sum of 2 quarters · filed 2024-05-07 | $1.12M derived: sum of 3 quarters · filed 2024-05-07 | $1.12M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-11 | $0.00 10-K · filed 2024-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |